Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|VHL inact mut||renal cell carcinoma||predicted - sensitive||mTORC1 Inhibitor||Everolimus||Phase II||Actionable||In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Afinitor (everolimus) had a trend towards improved in progression free survival when stratified by the presence (median PFS=8.6 months, n=15) or absence (median PFS=5.5 months, n=16) of deleterious VHL mutations (PMID: 26951309).||26951309|
|VHL inact mut||renal cell carcinoma||predicted - sensitive||VEGFR Inhibitor (Pan)||Alpha 2 Interferon + Bevacizumab||Clinical Study - Cohort||Actionable||In a retrospective analysis, VHL alterations did not impact overall survival or objective response in renal cell carcinoma patients treated with a VEGF-targeted therapy, including Avastin (bevacizumab) and Alpha 2 Interferon combination therapy, but were associated with a prolonged time to progression (PMID: 16827904).||16827904|
|VHL inact mut||renal cell carcinoma||no benefit||GDC-0980||Phase II||Actionable||In a retrospective analysis from a Phase II clinical trial, patients with metastatic renal cell carcinoma treated with Apitolisib (GDC-0980) had no difference in progression free survival when stratified by the presence (n=5) or absence (n=17) of deleterious VHL mutations (PMID: 26951309).||26951309|
|VHL inact mut||clear cell renal cell carcinoma||conflicting||PT2399||Preclinical - Pdx||Actionable||In a preclinical study, PT2399 had variable impact on tumor growth in clear cell renal cell carcinoma (ccRCC) cell line and patient-derived xenograft (PDX) models with defective VHL, with decreased tumor growth in a VHL-defective ccRCC PDX model and some VHL-defective ccRCC cell line xenograft models, and no tumor suppression in other cell line xenograft models (PMID: 27595393).||27595393|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03108066||Phase II||PT2385||PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma||Active, not recruiting|
|NCT04266912||Phase Ib/II||Avelumab + Berzosertib||Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors||Recruiting|